Список проголосовавших за комментарий "The Oxford/AstraZeneca Covid-19 vaccine does not appear to offer protection against mild and moderate disease caused by the viral variant first identified in South Africa, according to a study due to be published on Monday.<br/> <br/> Although none of the more than 2,000 patients in the study died or was hospitalised, the findings, which have not yet been peer reviewed, could complicate the race to roll out vaccines as new strains emerge.<br/> <br/> In both the human trials and tests on the blood of those vaccinated, the jab showed significantly reduced efficacy against the 501Y.V2 viral variant, which is dominant in South Africa, according to the randomised, double-blind study seen by the Financial Times."